While receiving a metastatic cancer diagnosis can be overwhelming, it is important to keep in mind that not all cancers are ...

Boston Cell Standards, Inc. (BCS), a private company bringing modern Quality tools and practices to Clinical ...

Flaig: It has been a remarkable 10 years for bladder cancer. If you think back to 10 or 15 years ago, we had no new ...

Caris Life Sciences aims to standardize MET immunohistochemistry testing for non-squamous non-small cell lung cancer to enhance molecular insights and treatment personalization. MET protein expression ...

Researchers from Lund University (Sweden) have investigated the tumor immune microenvironment of primary triple-negative breast cancer using digital image analysis of IHC-stained immune cells. To do ...

Enhancing Precision in Detecting Severe Immune-Related Adverse Events: Comparative Analysis of Large Language Models and International Classification of Disease Codes in Patient Records Table 1.

The FDA granted tumor-agnostic accelerated approval to trastuzumab deruxtecan (Enhertu) for previously treated unresectable or metastatic HER2-positive (immunohistochemistry [IHC] 3+) solid cancers.

BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc., a genomics company committed to transforming cancer care, today announced that it has expanded its immunohistochemistry (IHC) test offerings to ...

Prognostic Biomarkers and Immunotherapeutic Insights of Circulating Tumor DNA Analysis in Advanced Esophageal Squamous Cell Carcinoma From SCRUM-MONSTAR GOZILA Substudy We retrospectively analyzed 345 ...

Continued approval of this tumor agnostic indication is contingent upon verification of clinical benefit in a confirmatory trial. The Food and Drug Administration (FDA) has granted accelerated ...